Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

78 results about "Sphingolipid" patented technology

Sphingolipids are a class of lipids containing a backbone of sphingoid bases, a set of aliphatic amino alcohols that includes sphingosine. They were discovered in brain extracts in the 1870s and were named after the mythological sphinx because of their enigmatic nature. These compounds play important roles in signal transduction and cell recognition. Sphingolipidoses, or disorders of sphingolipid metabolism, have particular impact on neural tissue. A sphingolipid with an R group consisting of a hydrogen atom only is a ceramide. Other common R groups include phosphocholine, yielding a sphingomyelin, and various sugar monomers or dimers, yielding cerebrosides and globosides, respectively. Cerebrosides and globosides are collectively known as glycosphingolipids.

Strain for degrading aspartame, algal-bacterial symbiotic system and application of algal-bacterial symbiotic system

The invention discloses a bacterial strain for degrading aspartame, a bacterial-algae symbiotic system and application of the bacterial strain and the bacterial-algae symbiotic system, the bacterial strain is corn sphingomonas zeae NCU J1, and the preservation number of the bacterial strain is CCTCC (China Center for Type Culture Collection) NO: M 20251462. And an algal-bacterial symbiotic system is constructed by adopting an oriented symbiotic combination of the corn sphingomonas NCU J1 and the chlorella sp. The corn sphingomonas NCU J1 can metabolize an artificial sweetening agent aspartame and degradation products thereof, metabolism complementation can be achieved through an algal-bacterial symbiotic interface, and bacteria preferentially promote aspartame to be subjected to photohydrolysis to generate degradation products such as diketopiperazine derivatives. The microalgae synchronously start isomerism enzymatic reaction to convert degradation products such as diketopiperazine derivatives into low-toxicity products, the risk of secondary pollution is reduced by 40% or above compared with that of a traditional physical and chemical method, 150 mg / L aspartame can be efficiently degraded within 2 days, generation of derivatives of aspartame can be greatly reduced, secondary pollution is reduced, and the method is suitable for industrial production. And the method has a good application prospect in the aspect of rapidly treating aspartame-containing wastewater.
Owner:NANCHANG UNIV

Application of dsRNA of targeting sphingolipid C-4 hydroxylase coding gene

ActiveCN120192969ABiocideFungicidesBiotechnologySphingolipid synthesis
The invention belongs to the technical field of RNA biological prevention and treatment, and particularly relates to application of dsRNA of a targeting sphingolipid C-4 hydroxylase coding gene. The invention provides application of targeted sphingolipid C-4 hydroxylase coding gene dsRNA in prevention and treatment of crop anthracnose and / or preparation of products for prevention and treatment of crop anthracnose, and the targeted sphingolipid C-4 hydroxylase coding gene dsRNA is obtained by transcription of partial sequence of a sphingolipid synthetase coding gene CsSUR2. The targeting sphingolipid C-4 hydroxylase coding gene dsRNA is loaded on the nano layered double hydroxide, so that the pathogenicity of colletotrichum gloeosporioides and mango colletotrichum gloeosporioides can be obviously reduced, and the application prospect of preventing crop anthracnose is achieved.
Owner:HAINAN UNIVERSITY SANYA NANFAN RESEARCH INSTITUTE

Application of metabolic marker in preparation of product for monitoring heart failure and product

The metabolic marker can be used for early diagnosis of heart failure, has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result, provides a basis for clinical decision, provides a certain basis for subsequent fundamental research and clinical research, and has potential application and research values. The metabolic marker comprises one or more of 1-(4-nitrophenyl) piperidine, sphingolipid d19: 3 / 23: 0, phosphatidyl ethanolamine 16: 1e / 22: 5, phosphatidyl ethanolamine 16: 1e / 22: 6, sphingolipid d14: 0 / 22: 1, 3-phosphoglyceric acid, phosphatidylcholine 15: 0 / 20: 4, phosphatidylcholine o-16: 1 / 18: 0, phosphatidylcholine 14: 0e / 20: 1, phosphatidylcholine 17: 0 / 18: 5, betaine, phosphatidylcholine 15: 0 / 18: 2 and phosphatidylcholine 18: 5e / 20: 4.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Modified lipid compositions and uses thereof

Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol, glucosylcholesterol; and modified by (b) ionizable lipids. The present disclosure also includes a method for preparing a modified lipid composition, the method comprises reconstituting (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol and / or glucosylcholesterol in the presence of (b) ionizable lipids to produce the modified lipid composition, and loading one or more heterologous functional agents into the modified lipid composition.
Owner:SAIL BIOPHARMACEUTICAL CO LTD

Methods and Compositions for Treating Infections

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.
Owner:DECOY THERAPEUTICS INC

Nanoemulsion composition, nanometer skin care product, preparation method and application

The invention provides a nano-emulsion composition, a nano skin care product, a preparation method and application, the nano-emulsion composition comprises a nano-emulsion and nucleic acid loaded on the surface of the nano-emulsion, and the nano-emulsion comprises a functional component, an emulsifier, an emollient, an antioxidant, a humectant and water; the functional component comprises a barrier repair lipid, the barrier repair lipid comprises sphingolipid, the sphingolipid comprises phytosphingosine, and the barrier repair lipid further comprises one or more of ceramide, free fatty acid and cholesterol; the mass ratio of the nucleic acid in the nanoemulsion composition is 0.1%-0.6%. The nanoemulsion composition has excellent permeability, so that the skin permeability of the nucleic acid is improved, and the bioavailability of the nucleic acid is improved; meanwhile, the nucleic acid can be specifically bound with adenosine A2A receptors distributed on keratinocytes, so that the binding speed of the nano-emulsion and the cells can be increased, the absorption and action effects of the nano-emulsion are specifically promoted, and the resistance of the skin to light aging is improved.
Owner:BEIJING TECH & BUSINESS UNIV

CAR-T Cell Culture Method and Its Application in Cancer Treatment

The present application provides a method for culturing CAR-T cells and its application in tumor treatment, belonging to the field of biomedical technology. Specifically, the method includes culturing CAR-T cells with sphingolipid metabolites. Culturing CAR-T cells with sphingolipid metabolites in vitro can significantly increase the killing efficiency of CAR-T cells, slow down the tumor growth rate, extend the survival period of patients / animals, and will not impose an additional metabolic burden on the body, with lower toxic and side effects. In addition, this method does not perform any modification on the cells themselves, thus reducing the unknown potential risks for patients / animals due to the reinfusion of various modified adjuvants, and therefore has higher safety.
Owner:INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT

Sphingolipid based hair treatment

The present invention provides the use of at least one sphingolipid for a hair treatment for inducing hair growth and / or inhibiting hair loss, including eyelashes and eyebrows. Said sphingolipid is preferably a ceramide having a fatty acid with a long hydrocarbon chain of C18-C24, mostly C20-C22, and a phytosphingosine base. Furthermore, and advantageously, the treatment is global, capable to also improve the properties of the scalp and hair themselves.
Owner:SEDERMA SA +1

A nanoliposome containing sea cucumber ganglioside extract with neuroprotective activity and its preparation method

This invention provides a sea cucumber ganglioside extract nanoliposome with neuroprotective activity and its preparation method. The preparation steps are as follows: thawed frozen ready-to-eat sea cucumber, chopped, freeze-dried, pulverized, and sieved to obtain freeze-dried powder. The powder is then extracted using supercritical CO2 extraction and rotary evaporation to remove the solvent. This powder is then dissolved in anhydrous ethanol with soybean lecithin and β-sitosterol as the oil phase, mixed with PBS buffer, stirred, and hydrated to obtain a proemulsion. After centrifugation, the precipitate is resuspended and sonicated to obtain the product. This invention uses supercritical CO2 extraction, and the extract contains 59.70 μg / g of gangliosides, with glycosphingolipids accounting for 96.372% of sphingolipids, resulting in enrichment of the target components. Simultaneously, these nanoliposomes significantly delay Aβ1-42-induced paralysis. The 30 μg / mL group showed a 2.75-fold increase in motor ability and a 30% increase in reproductive function compared to the control group, and a 47% reduction in ROS levels. The neuroprotective effect is superior to that of the unencapsulated extract, providing a new approach for adjuvant intervention in neurodegenerative diseases such as Alzheimer's disease, and has broad application prospects in the functional food field.
Owner:SHANGHAI JIAOTONG UNIV +1

Liposome, medicine liposome compound and preparation method and application thereof

The invention discloses lipidosome, a medicine lipidosome compound and a preparation method and application of the medicine lipidosome compound. The liposome comprises the following components in parts by mass: 10-65 parts of saturated phospholipid; 25 to 75 parts of unsaturated phospholipid; 0.5 to 15 parts of a trigger lipid; the trigger lipid is sphingolipid and / or cholesterol; the mass ratio of the saturated phospholipid to the unsaturated phospholipid is (0.20-2.50): 1. When the lipidosome is used for drug encapsulation, high encapsulation efficiency can be guaranteed, high activity of drugs can be maintained, the lipidosome can be stably stored, and a universal carrier is provided for drugs with different physicochemical properties (especially highly hydrophilic drugs, such as protein drugs and nucleic acid drugs).
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE

MALDI-FT-ICR mass spectrometry probe for single-chain sphingolipid detection and methods of making and using the same

The application discloses a MALDI-FT-ICR mass spectrum probe for single-chain sphingolipid detection and a preparation method and a use method thereof, and relates to the technical field of analytical testing. The MALDI-FT-ICR mass spectrum probe for single-chain sphingolipid detection has the general structure of: the preparation method comprises the following steps: 4-pyridine propionic acid or pyridine 4-propenoic acid is reacted with salicylaldehyde or a salicylaldehyde derivative in a protective atmosphere. The use method comprises the following steps: different concentrations of sphingosine methanol solutions are prepared, the stock solution of the probe is added into each concentration of the sphingosine methanol solution, and a mixed solution is obtained; the mixed solution is mixed with a matrix methanol solution, is spotted on a target plate, is dried at room temperature, and then is subjected to MALDI analysis; and a standard curve is drawn with different concentrations of the sphingosine in the step S1 as the horizontal coordinate and the MALDI ion signal intensity of the product obtained in the step S1 as the vertical coordinate. The mass spectrum probe provided by the application has high sensitivity, low cost and high throughput.
Owner:HANGZHOU INST FOR ADVANCED STUDY UCAS

Targeted glucosinolate mass spectrum database and construction method and application thereof

The invention provides a glucosinolate mass spectrum database and a construction method and application thereof, and the database records more than 120 types of glucosinolate molecular information which is far better than that of the existing database. According to the pretreatment and detection method for the targeted thioglycoside group of the biological sample, solid-phase extraction and a micro-nano mass spectrum chip are combined, thioglycoside group mass spectrum signals are obtained in batches under the condition of no matrix spraying, the coverage rate is wide, the flux is high, the detection speed is high, thioglycoside group information of multiple samples can be obtained at a time in an automatic detection mode, and the detection method is suitable for large-scale popularization and application. The obtained thioglycoside spectrogram is high in stability, and in-batch and inter-batch CVlt is achieved under the condition that no internal standard is added; by combining with an established thioglycoside mass spectrum database, a novel method strategy is provided for marker mining and clinical application of diseases related to sphingolipid.
Owner:HANGZHOU WELL HEALTHCARE TECH CO LTD +1

Production of ceramides

The present invention relates to a novel and efficient process for the production of sphingolipids via N-acylation of hemolytic sphingolipids, such as o-red-phytosphingosine, salts thereof or analogs thereof. The process comprises the use of an ester as an acylating agent in the presence of a base and in a hydrocarbon solvent, and is particularly useful for the production of ceramides.
Owner:CATAYA BIO (SHANGHAI) CO LTD

Ointments for treating dry skin

A composition for treating dry skin includes therapeutically active concentrations of one or more skin protecting lipids in an oleaginous base. The skin protecting lipids can include a sphingolipid and at least one oil. The composition is intended for application on the skin surrounding the eyes. The composition is configured to form a protective, occlusive layer that can moisturize the skin and reduce inflammation and itching without stinging, burning, or stripping the skin. According to an exemplary embodiment, the composition is formulated as a high viscosity ointment or gel.
Owner:OCUSOFT INC

Biological production of gangliosides in recombinant host cells

PendingCN120858172AFungiTransferasesGlycosphingolipidPharmaceutical drug
In various embodiments, provided herein are host cells, methods, and pharmaceutical compositions, including complex sphingolipids, such as monosialic acid ganglioside 1 (GM1), monosialic acid ganglioside 2 (GM2), and monosialic acid ganglioside 3 (GM3). In some embodiments, the present disclosure provides biological production of glycosphingolipids. In still further embodiments, the present disclosure provides for the biological production of gangliosides.
Owner:RECOMBIA BIOSCIENCES INC

Lipid nanosystems

The present invention relates to a lipid system comprising: a) at least one oil, b) at least one ionizable lipid, c) at least one sphingolipid, and d) at least one lipid-polymer, with the proviso is that the lipid system does not comprise cholesterol. The present invention also uses of the lipid system in therapy.
Owner:DIVERSA TECHNOLOGIES SL

Novel glycosynthase

The present invention relates to a novel glycosynthase, especially an endoglycoceramide synthase, and to a method for the glycosylation of sphingolipids.
Owner:CARBOCODE SA

Application of ceramide in the control of rice blast fungus

PendingCN122074492AIncrease coercion effectIncrease contentBiocideFungicidesBiotechnologySphingolipid metabolism
The application of ceramide in the control of rice blast fungus falls within the field of biological control. This invention relates to the application of ceramide in the control of rice blast fungus: a combination of ceramide and lipopeptides is used for the control of rice blast fungus. Exogenous addition of ceramide significantly enhances the stress effect of lipopeptides on rice blast fungus. It also enhances the abnormal accumulation of glycogen and lipid droplets in conidia, promotes the bursting of ROS, and increases intracellular ceramide and calcium... 2+ The invention increases the content of malondialdehyde (MDA) in mycelium, enhances membrane lipid peroxidation, and decreases ergosterol content. Furthermore, it inhibits the expression of ergosterol synthesis genes, UPR target genes, and sphingolipid metabolism-related genes. This invention develops a highly efficient natural agent against rice blast by combining exogenous Cer with lipopeptides. This agent effectively reduces the pathogenicity of rice blast fungus and significantly inhibits its infection of rice, laying the foundation for the development of novel biological control agents.
Owner:HEILONGJIANG UNIV

Matuota novosphingobium hpd1 for degrading high-efficiency fluazifop-butyl acid and application thereof

PendingCN122648286ANovosphingobium sp.Pesticide residue
The present application relates to the field of microbial technology, and particularly relates to a strain of Matuura sphingolipid bacteria HPD1 for degrading high-efficiency fluazifop-butyl acid and application thereof, the Matuura sphingolipid bacteria HPD1 is classified and named as Novosphingobium mathurense , which was preserved in the China General Microbiological Culture Collection Center on May 9, 2026, with a preservation number of CGMCC No. 38610 and a preservation address of No. 1, Beichen West Road, Chaoyang District, Beijing. The Matuura sphingolipid bacteria HPD1 and the microbial inoculant thereof can effectively degrade high-efficiency fluazifop-butyl acid in a wide pH and temperature range, can be used as excellent functional bacteria for degrading pesticide residues, and can be used in the biological remediation of residual high-efficiency fluazifop-butyl acid in water bodies, contaminated soil, coastal wetland sediments and Spartina alterniflora treatment areas, and can provide functional bacteria resources that can be repeatedly obtained and environmentally friendly microbial remediation technology.
Owner:EAST CHINA NORMAL UNIV

Pharmaceutical or cosmetic composition for reducing sebum production on scalp

Composition (C) comprising, for 100% by mass: 20% to 80% by mass of at least one sphingolipid (a1), 10% to 50% by mass of a digalactosyl diglyceride (a2), and 1% to 30% by mass of at least one phospholipid (a3), for use in a therapeutic treatment method for preventing or limiting sebum production on the scalp. A pharmaceutical composition (Cp) and a food supplement (Ca) comprising said composition (C). A non-therapeutic use of the food supplement (Ca) and a non-therapeutic implementation method.
Owner:SOC DEXPLOITATION DE PROD POUR LES IND CHEM SEPPIC

Ointments for treating dry skin

A composition for treating dry skin includes therapeutically active concentrations of one or more skin protecting lipids in an oleaginous base. The skin protecting lipids can include a sphingolipid and at least one oil. The composition is intended for application on the skin surrounding the eyes. The composition is configured to form a protective, occlusive layer that can moisturize the skin and reduce inflammation and itching without stinging, burning, or stripping the skin. According to an exemplary embodiment, the composition is formulated as a high viscosity ointment or gel.
Owner:OCUSOFT INC

Use of pig's tooth saponin in preparation of drugs for treating cerebral ischemia-reperfusion injury

The application provides application of pig's tooth saponin volatile oil in preparation of a medicine for treating cerebral ischemia-reperfusion injury, and a preparation method of the pig's tooth saponin volatile oil is as follows: pig's tooth saponin decoction pieces are taken, water and n-hexane are added, and volatile oil is obtained through steam distillation; the volatile oil is collected, anhydrous sulfuric acid is added, and water is removed; and the mixture is left overnight to obtain the pig's tooth saponin volatile oil. The prepared pig's tooth saponin volatile oil acts on key target points of VEGFA, SRC, MAPK8, PIK3CA and TNF through active ingredients of paeonol, linalool, methyl eugenol, anethole and eugenol, regulates multiple signal pathways of sphingolipids, TNF and VEGF, inhibits cell oxidative stress injury, inhibits release of inflammatory factors and regulates nerve function, so as to play a role in treating cerebral ischemia-reperfusion injury, and lay a foundation for further in-depth study on a treatment mechanism of pig's tooth saponin in treating 'opening the orifices and connecting the heart and the lung'.
Owner:GUIYANG COLLEGE OF TRADITIONAL CHINESE MEDICINE

Application of metabolic marker in preparation of product for monitoring CsA renal toxicity and product

The invention discloses application of a metabolic marker in preparation of a product for monitoring CsA renal toxicity and the product, and the metabolic marker can be used for monitoring CsA renal toxicity and is high in sensitivity, rapid, convenient and accurate and reliable in result. The metabolic marker is one or more of the following substances: phospholipid 18: 1 / 20: 0, phospholipid 20: 1 / 14: 1, lysophospholipid 18: 3, sphingolipid d18: 0 / 16: 1OH, sphingolipid d18: 0 / 24: 1OH and monoacylglycerol 20: 4 / 0: 0 / 0: 0.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Saposin-a derived peptides and uses thereof

Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
Owner:CHILDRENS MEDICAL CENT CORP

Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin

ActiveUS12485117B2Nervous disorderHydrolasesLipid storageLysosome
The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.
Owner:WYLDER NATION FOUNDATION

Anc80 encoding sphingolipid-metabolizing proteins

ActiveUS12618059B2HydrolasesTransferasesIntracellularAcid Ceramidase
The present disclosure pertains to the use of an Anc80 viral vector that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the Anc80 vector reduces high levels of ceramide in the cell that lead to cell death or senescence.
Owner:MT SINAI SCHOOL OF MEDICINE

Medicinal and edible rice paste formula capable of tonifying spleen, eliminating dampness and preventing encephalatrophy

The invention discloses a formula of medicinal and edible rice paste capable of tonifying spleen, clearing damp and preventing encephalatrophy. Comprising the following components: 10-20 parts of soybeans, 8-15 parts of small red beans, 6-12 parts of fried coix seeds (fried until the surfaces are light golden yellow and have no burnt spots), 5-10 parts of Chinese yams, 4-8 parts of white poria cocos, 3-7 parts of radix puerariae, 3-6 parts of fried gordon euryale seeds (the frying standard is that the surfaces are slightly burnt and have light burnt fragrance, and the particle size is 2-3mm), 2-5 parts of dried longan, 15-25 parts of millet and 0.5-1.5 parts of shredded dried tangerine peels. The invention belongs to the technical field of medicinal and edible foods, and particularly relates to a medicinal and edible rice paste formula for tonifying spleen, clearing damp and preventing encephalatrophy.
Owner:夏俊杰